Revenue Breakdown
Composition ()
No data
Revenue Streams
Universe Pharmaceuticals Inc (UPC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sales of TCMD products, accounting for 50.8% of total sales, equivalent to $9.37M. Another important revenue stream is Sales of third-party products. Understanding this composition is critical for investors evaluating how UPC navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Universe Pharmaceuticals Inc maintains a gross margin of 34.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25.42%, while the net margin is -35.89%. These profitability ratios, combined with a Return on Equity (ROE) of 2.66%, provide a clear picture of how effectively UPC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, UPC competes directly with industry leaders such as LYRA and AZTR. With a market capitalization of $1.53M, it holds a significant position in the sector. When comparing efficiency, UPC's gross margin of 34.57% stands against LYRA's 100.00% and AZTR's N/A. Such benchmarking helps identify whether Universe Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
